Selective cyclo-oxygenase-2 inhibitors: Cardiovascular and gastrointestinal toxicity

Digestive and Liver Disease

Volumn 33, Issue SUPPL. 2, 2001, Pages

  Wallace, J L ^a   Muscara M N ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclo oxygenase; Hypertension; Thrombosis; Ulcer

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ENALAPRIL; IBUPROFEN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CORONARY RISK; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG MARKETING; DRUG SELECTIVITY; DRUG USE; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY; MOUSE; MUCOSA INFLAMMATION; MUCOSAL IMMUNITY; NONHUMAN; RAT; STROKE; THROMBOSIS;

EID: 0035678142     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80155-9     Document Type: Article

References (46)

1. L-745,337: A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats
2. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic
3. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
4. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach
5. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial
6. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
8. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
9. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
10. Cyclooxygenase-2 selective and nitric oxide-releasing non-steroidal anti-inflammatory drugs and gastric mucosal responses
11. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
12. Impaired mucosal defence to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2
13. Selective COX-2 inhibitors and human inflammatory bowel disease
14. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
15. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
16. Aspirin induces a rapid up-regulation of cyclooxygenase-2 expression in the rat stomach
17. Induction of cyclooxygenase-1 and -2 in the rat stomach during endotoxemia: Role in resistance to damage
18. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach
19. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
20. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure
21. NSAID-induced gastric damage in the rat: Requirement for inhibition of both cyclooxygenase-1 and -2
22. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
23. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
24. Non-steroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
25. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process
26. Nephrotoxicity of non-steroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
27. 2 formation
28. The clinical significance of inhibition of renal prostaglandin synthesis
29. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
30. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction
31. Localization of cyclooxygenase-1 and -2 in adult and foetal human kidney: Implication for renal function
32. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
33. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-II
34. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse
35. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
36. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
37. Aspirin as an antiplatelet drug
38. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 inhibitors. A report of four cases
39. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
40. Limited anti-inflammatory efficacy of cyclooxygenase-2 inhibition in carrageenan-airpouch inflammation
41. In vivo anti-thrombotic effects of NCX-4016: A nitric oxide-releasing aspirin derivative
42. Adaptation of the gastric mucosa to repeated administration of aspirin in the rat
43. Adaptation of the rat gastric mucosa to aspirin requires mucosal contact
44. Gastric adaptation to non-steroidal anti-inflammatory drugs in man
45. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis